Shares of Omnicell, Inc. (NASDAQ:OMCL) have been given an average rating of “Buy” by the twelve analysts that are presently covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $49.00.

A number of equities research analysts have commented on the stock. BidaskClub downgraded shares of Omnicell from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Piper Jaffray Companies reissued a “hold” rating and issued a $40.00 price objective on shares of Omnicell in a research report on Sunday, July 30th. Cantor Fitzgerald reissued a “buy” rating and issued a $47.00 price objective on shares of Omnicell in a research report on Tuesday, July 25th. Craig Hallum increased their price objective on shares of Omnicell from $46.00 to $52.00 and gave the company a “buy” rating in a research report on Friday, July 28th. Finally, Dougherty & Co increased their price objective on shares of Omnicell from $45.00 to $49.00 and gave the company a “buy” rating in a research report on Friday, July 28th.

TRADEMARK VIOLATION WARNING: “Omnicell, Inc. (OMCL) Given Consensus Rating of “Buy” by Brokerages” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://www.dailypolitical.com/2017/08/08/omnicell-inc-omcl-given-consensus-rating-of-buy-by-brokerages.html.

In related news, Chairman Randall A. Lipps sold 40,000 shares of the stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $49.76, for a total value of $1,990,400.00. Following the transaction, the chairman now directly owns 196,551 shares of the company’s stock, valued at approximately $9,780,377.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Chairman Randall A. Lipps sold 37,500 shares of the stock in a transaction on Friday, July 28th. The shares were sold at an average price of $46.00, for a total transaction of $1,725,000.00. Following the completion of the transaction, the chairman now directly owns 196,551 shares in the company, valued at $9,041,346. The disclosure for this sale can be found here. Insiders sold a total of 149,675 shares of company stock worth $6,754,894 over the last ninety days. Insiders own 3.77% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. increased its position in Omnicell by 139,475.2% in the first quarter. BlackRock Inc. now owns 4,487,343 shares of the company’s stock worth $182,412,000 after buying an additional 4,484,128 shares during the period. Vanguard Group Inc. boosted its stake in shares of Omnicell by 5.5% in the first quarter. Vanguard Group Inc. now owns 1,860,299 shares of the company’s stock worth $75,622,000 after buying an additional 97,345 shares in the last quarter. Champlain Investment Partners LLC boosted its stake in shares of Omnicell by 6.2% in the first quarter. Champlain Investment Partners LLC now owns 1,698,140 shares of the company’s stock worth $69,029,000 after buying an additional 99,075 shares in the last quarter. Conestoga Capital Advisors LLC boosted its stake in shares of Omnicell by 6.1% in the second quarter. Conestoga Capital Advisors LLC now owns 1,606,601 shares of the company’s stock worth $69,245,000 after buying an additional 92,735 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of Omnicell by 11.0% in the first quarter. Bank of New York Mellon Corp now owns 1,190,691 shares of the company’s stock worth $48,401,000 after buying an additional 118,201 shares in the last quarter. 96.35% of the stock is currently owned by hedge funds and other institutional investors.

Omnicell (OMCL) traded down 0.49% during midday trading on Tuesday, hitting $51.20. 116,586 shares of the stock traded hands. The stock’s market cap is $1.91 billion. The company has a 50-day moving average price of $43.70 and a 200 day moving average price of $40.34. Omnicell has a one year low of $30.35 and a one year high of $51.97.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, July 27th. The company reported $0.02 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.02. Omnicell had a negative net margin of 1.14% and a positive return on equity of 0.41%. The company had revenue of $180.90 million for the quarter, compared to the consensus estimate of $174.08 million. During the same period in the prior year, the firm posted $0.38 EPS. The company’s quarterly revenue was up 4.6% compared to the same quarter last year. Equities research analysts anticipate that Omnicell will post $1.31 earnings per share for the current year.

About Omnicell

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Analyst Recommendations for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.